FDA Approves Topical Tapinarof for Atopic Dermatitis ...Middle East

Medscape - News
In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was approximately 80 consecutive days. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Topical Tapinarof for Atopic Dermatitis )

Also on site :